Article

Intel introduced its Core Series 2 processors, designed for mission-critical edge applications, at Embedded World 2026. The processors provide improved performance metrics, claiming up to 4.4 times lower PCIe latency and 3.8 times better deterministic performance compared to AMD's Ryzen 7 9700X.

Alongside this, Intel unveiled the Edge AI Suite for Health & Life Sciences, which offers tools for developing AI-enabled patient monitoring systems. The suite supports multimodal workloads running locally on Intel hardware. Both the Core Series 2 and the Edge AI Suite are expected to enhance automation in healthcare and industrial settings, with general availability slated for Q2 2026.